MDNA.TO (TSX – Canada), MDNAF (OTCQB – USA) Medicenna is a clinical-stage immunotherapy company developing novel, selective IL-2, IL-4, and IL-13 Superkine molecules exclusively in-licensed from Stanford University. The Superkines are engineered versions of naturally circulating immune system cytokines, designed to enhance cancer-killing properties of immune cells while enabling systemic therapeutic dosing by minimizing their […]
October 25th Biotech Update
A bounce feels good but as had been the case it really means nothing unless we can break above the lower high (which in this case is around $72). Every one of these bounces has the chance to do so but as you know my mantra has been that we are likely to see $62 […]
November 3rd Biotech Update
Guess what? The Fed speaks and the market declines (along with the sector). As I said the earnings season has been quite good for the sector but as I have also said one should not try and fight the Fed. As long as the perception is higher rates for longer, then I do not see […]
May 25th Biotech Update
It looked as though the sector tried to reverse a couple of times but it ended up being a red day. It would have been nice to get a good red to green reversal with follow through today but at least we are starting green today. It is important to have a good day today […]
March 14th Biotech (and Ukraine) Update
Not much has changed in the Ukraine. This is probably a positive for the market but this stalemate cannot last indefinitely. If the Ukrainians are successfully hitting the Russian supply lines (as it appears) then the Russian forces will soon (another week or so) have very little supplies left that they will be unable to […]
April 28th Biotech Update
It has been a rough start to earnings season. The sector has done pretty well considering, although it might highlight the need for large caps to do more deals as clearly they are not generating enough growth with their current pipelines and approved products. It is still early in earning seasons and it can still […]
July 30 Biotech Update
Tell me if you heard this before. Good news in the sector that moves individual stocks and yet little effect on the broader sector. We have yet another day with good news (clinical and earnings) and yet the sector is barely green. Granted the broader market is red but this has become a trend. I […]
February 7 Biotech Update
We start off a little weak this morning, which is not completely unexpected given that we are at the top end of the recent range. Obviously it would be nice to see a breakout above the range to start another leg higher but range bound trading after the recent run is not bad at this […]
April 2 Biotech Update
Thursday was not a bad follow through for the sector. I am still not convinced that we are out of the forest quite yet but we are at least further away from the abyss that was staring at the sector earlier last week. This week looks to be quiet to start as there is not […]
October 21 Biotech Update
Clearly the sector did not turn the corner after the presidential debate even though it should have assuaged concerns over the importance of drug pricing to the candidates. The sector had a small recovery and with the positive news released last night, this should have been a nice tailwind. Any sort of early pop has […]
Platform and Specialty Pharmaceutical Companies can bolster Big Pharma
The pharmaceutical industry is in a weak state, with an impending “patent cliff” that is forcing Big Pharma to reorganize and refocus. In 2011, roughly $20 billion in branded US sales dollars are “at risk” to patent expiry and generic competition. The pinnacle will be reached in 2013 and will subside after 2015. Fiscal Year […]
